Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant epithelial neoplasm arising in the paranasal sinus.
Biomarker and diagnostic research for paranasal sinus carcinoma has been reported in the published literature.
10 clinical trials registered, 3 recruiting. Interventions under study include procedural interventions, other interventions, drug therapy, and biologic therapy. Pipeline includes 5 PHASE2, 2 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT02012699](https://clinicaltrials.gov/study/NCT02012699) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 3:56 PM UTC
Integrated Cancer Repository for Cancer Research |
— |
University of Nebraska |
RECRUITING |
[NCT05483374](https://clinicaltrials.gov/study/NCT05483374) | The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers | — | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | RECRUITING |
[NCT06940180](https://clinicaltrials.gov/study/NCT06940180) | Toripalimab With Chemotherapy for Sinus Cancer | PHASE2 | Dana-Farber Cancer Institute | RECRUITING |
187 publications have been identified in PubMed for paranasal sinus carcinoma. Research spans Review / Meta-Analysis (27%), Case Report / Case Series (20%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 50 | 27% |
Patient case studies | 38 | 20% |
Disease patterns and progression | 32 | 17% |
Clinical study results | 24 | 13% |
Laboratory research | 20 | 11% |
Testing and diagnosis research | 18 | 10% |
New treatment approaches | 5 | 3% |
Park E (2026). [PMID: 41720480](https://pubmed.ncbi.nlm.nih.gov/41720480/). *Cancer Med*. [Epidemiology / Natural History]
Hassan CH (2026). [PMID: 41720745](https://pubmed.ncbi.nlm.nih.gov/41720745/). *Eur Ann Otorhinolaryngol Head Neck Dis*. [Review / Meta-Analysis]
Akutsu H (2026). [PMID: 42036861](https://pubmed.ncbi.nlm.nih.gov/42036861/). *No Shinkei Geka*. [Review / Meta-Analysis]
Ma J (2026). [PMID: 41589367](https://pubmed.ncbi.nlm.nih.gov/41589367/). *Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi*. [Epidemiology / Natural History]
Ye Z (2026). [PMID: 41328494](https://pubmed.ncbi.nlm.nih.gov/41328494/). *Head Neck*. [Diagnostic / Biomarker]
Tham T (2026). [PMID: 40899433](https://pubmed.ncbi.nlm.nih.gov/40899433/). *The Laryngoscope*. [Epidemiology / Natural History]
Vinciguerra A (2026). [PMID: 41025537](https://pubmed.ncbi.nlm.nih.gov/41025537/). *International forum of allergy & rhinology*. [Review / Meta-Analysis]
Butt L (2026). [PMID: 42028164](https://pubmed.ncbi.nlm.nih.gov/42028164/). *BJR Case Rep*. [Case Report / Case Series]
Cao C (2026). [PMID: 41116339](https://pubmed.ncbi.nlm.nih.gov/41116339/). *Head Neck*. [Clinical Trial Publication]
Kim AH (2026). [PMID: 41273225](https://pubmed.ncbi.nlm.nih.gov/41273225/). *Laryngoscope*. [Epidemiology / Natural History]